Switch to: References

Add citations

You must login to add citations.
  1. Problem Formulation and Option Assessment (PFOA) Linking Governance and Environmental Risk Assessment for Technologies: A Methodology for Problem Analysis of Nanotechnologies and Genetically Engineered Organisms.Kristen C. Nelson, David A. Andow & Michael J. Banker - 2009 - Journal of Law, Medicine and Ethics 37 (4):732-748.
    Societal evaluation of new technologies, specifically nanotechnology and genetically engineered organisms, challenges current practices of governance and science. When a governing body is confronted by a technology whose use has potential environmental risks, some form of risk analysis is typically conducted to help decision makers consider the range of possible benefits and harms posed by the technology. Environmental risk assessment is a critical component in the governance of nanotechnology and genetically engineered organisms because the uncertainties and complexities surrounding these technologies (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
  • RAC Oversight of Gene Transfer Research: A Model Worth Extending?Nancy M. P. King - 2002 - Journal of Law, Medicine and Ethics 30 (3):381-389.
    Clinical gene transfer research has both a unique history and a complex and layered system of research oversight, featuring a unique review body, the Recombinant DNA Advisory Committee. This paper briefly describes the process of decision-making about clinical GTR, considers whether the questions, problems, and issues raised in clinical GTR are unique, and concludes by examining whether the RAC's oversight is a useful model that should be reproduced for other similar areas of clinical research.Clinical GTR is governed by the same (...)
    Download  
     
    Export citation  
     
    Bookmark   18 citations  
  • The Duty to Disclose Adverse Clinical Trial Results.S. Matthew Liao, Mark Sheehan & Steve Clarke - 2009 - American Journal of Bioethics 9 (8):24-32.
    Participants in some clinical trials are at risk of being harmed and sometimes are seriously harmed as a result of not being provided with available, relevant risk information. We argue that this situation is unacceptable and that there is a moral duty to disclose all adverse clinical trial results to participants in clinical trials. This duty is grounded in the human right not to be placed at risk of harm without informed consent. We consider objections to disclosure grounded in considerations (...)
    Download  
     
    Export citation  
     
    Bookmark   10 citations  
  • Genetics and bioethics: How our thinking has changed since 1969.LeRoy Walters - 2012 - Theoretical Medicine and Bioethics 33 (1):83-95.
    In 1969, the field of human genetics was in its infancy. Amniocentesis was a new technique for prenatal diagnosis, and a newborn genetic screening program had been established in one state. There were also concerns about the potential hazards of genetic engineering. A research group at the Hastings Center and Paul Ramsey pioneered in the discussion of genetics and bioethics. Two principal techniques have emerged as being of enduring importance: human gene transfer research and genetic testing and screening. This essay (...)
    Download  
     
    Export citation  
     
    Bookmark   3 citations